Eloxx Pharmaceuticals Provides Program Updates On ELX-02 And ZKN-013

9/7/23 9:02:56 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ELOX alert in real time by email

Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations

Rebound in average UPCR 3-months post treatment provides further evidence that proteinuria remission in one out of three patients was drug related

All 3 Alport patients (100% response rate) treated with ELX-02 had biopsy confirmed disease regression, suggesting clinical benefit likely with longer treatment duration

Significant strategic interest in ZKN-013 following FDA approval to start Phase 1 single ascending dose (SAD) trial

Get the next $ELOX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ELOX

Date	Price Target	Rating	Analyst
12/17/2021	$4.00	Outperform	Oppenheimer
11/18/2021	$2.00 → $1.00	Neutral	HC Wainwright & Co.
11/11/2021	$3.00 → $2.00	Neutral	HC Wainwright & Co.
6/30/2021	$3.10	Buy	Mizuho

More analyst ratings

$ELOX
Press Releases

Fastest customizable press release news feed in the world

Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations Positive written FDA feedback and guidance from a pre-Investigational New Drug Application (PIND) meeting provides pathway to IND application submission to initiate a Phase 2 clinical trial in the US with ELX-02 in patients with nonsense mutation alport syndrome (NMAS) Secured binding commitment for additional $3.2 million financing to advance our clinical programs WATERTOWN, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (OTC:ELOX), a leader in ribosomal RNA-targeted gene
7/11/24 11:46:35 AM ET
$ELOX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02 to Discuss Planned next Study In Nonsense Mutation Alport Syndrome Signed Global Licensing Partnership for ZKN-013 with Almirall Pharmaceuticals with $3M upfront and up to $470M in milestones and Tiered Royalties on Global Sales New Paper Published on Autosomal Dominant Polycystic Kidney Disease (ADPKD) shows that ELX-02 treatment prevents cyst formation in diseased PKD organoids with nonsense mutations and a single healthy gene copy WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWI
4/16/24 7:30:00 AM ET
$ELOX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon resulting in nonfunctional protein production for example in recessive Dystrophic Epidermolysis Bullosa (RDEB), Junctional Epidermolysis Bullosa (JEB) and familial adenomatous polyposis (FAP) BARCELONA, Spain and WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC:ELOX) announced today that the companies have entered into an exclusive license agr
3/13/24 11:42:35 AM ET
$ELOX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$ELOX
Financials

Live finance-specific insights

Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients
Combination of subcutaneous ELX-02 with ivacaftor did not achieve statistical significance for efficacy endpoints in Phase 2 study in Class 1 CF ELX-02 was well tolerated with no drug-related serious adverse events observed Evidence of activity for ELX-02 observed; efficacy signal potentially confounded by variability due to low drug exposure Path forward for ELX-02 for the treatment of Class 1 CF to be determined together with CF Foundation Company to host conference call and webcast today, September 14, 2022, at 4:30 p.m. ET WATERTOWN, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare d
9/14/22 4:05:00 PM ET
$ELOX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients
ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat chloride reduction, an established surrogate for restoration of CFTR biological activity ELX-02 monotherapy results support advancement of ELX-02 into Phase 3 clinical development First patient dosed in Phase 2 ELX-02 expansion treatment arms evaluating combination with ivacaftor; topline data expected by the end of the first half of 2022 Company to host conference call and webcast Wednesday, November 17, 2021 at 8:30 am ET WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare dise
11/17/21 7:00:00 AM ET
$ELOX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Eloxx Pharmaceuticals Acquires Zikani Therapeutics
Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms Maximizes Potential for ELX-02 for Cystic Fibrosis in Phase 2 Development Adds Preclinical Stage Pipeline in Rare Diseases and Oncology Targeting RNA and Ribosomal Mutations Expects to File IND for First Oral Drug to Treat Patients with Recessive Dystrophic and Junctional Epidermolysis Bullosa (RDEB and JEB) Sumit Aggarwal, Zikani President and CEO, to Lead the Combined Company Eloxx to Issue Approximately 7.6 Million Shares to Zikani Stockholders Company to Host Investor Call at 8:30 a.m. ET, April 1 WALTHAM, Mass. and WATERTOWN, Mass., April 01, 2021 (GLOBE NEWSWIRE
4/1/21 7:45:00 AM ET
$ELOX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$ELOX
Leadership Updates

Live Leadership Updates

Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer
Cognito Therapeutics, a pioneer developing disease-modifying therapeutics to treat CNS diseases, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), to lead all finance-related and investor relations functions at the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017630946/en/Greg Weaver, CFO, Cognito Therapeutics (Photo: Business Wire) Mr. Weaver is a highly accomplished finance executive who brings more than 30 years of life sciences, financial and operations experience to Cognito. Most recently, he served as CFO of Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage oncology comp
10/17/23 8:00:00 AM ET
$ATAI
$ATOS
$ELOX
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer
SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces the appointment of Greg Weaver as the Company's new Chief Financial Officer (CFO). Mr. Weaver succeeds Kyle Guse. A short video interview with Mr. Weaver about his background and vision for Atossa can be found here: https://youtu.be/G6ZzHLh-qsQ Mr. Weaver brings more than 30 years of life sciences, financial and operations experience to the Company. Recently, he served as CFO of privately held BioIntelliSense, a commerc
6/1/23 9:10:00 AM ET
$ATAI
$ATOS
$ELOX
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Eloxx Pharmaceuticals Announces Changes to Board of Directors
Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra step down from the Eloxx board WATERTOWN, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the appointment of Lindsay Androski, JD, MBA to its board of directors and as a member of the Board's Audit Committee and Compensation Committee. Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr.
7/5/22 8:00:00 AM ET
$ELOX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Bellerophon Therapeutics (NASDAQ:BLPH) stock moved upwards by 17.1% to $0.12 during Friday's after-market session. Trading volume for this security closed at 2.1 million, accounting for 1394.7% of its average full-day volume over the last 100 days. The company's market cap stands at $1.4 million. Cingulate (NASDAQ:CING) stock increased by 12.59% to $0.58. The company's market cap stands at $10.0 million. Rain Oncology (NASDAQ:RAIN) stock rose 11.11% to $1.1. Rain Oncology's trading volume hit 98.3K shares by close, accounting for 45.0% of its average volume over the last 100 days. The company's market cap stands at $40.0 million. Artelo Biosciences (NASDAQ:ARTL) shares rose 9.72%
10/13/23 5:31:42 PM ET
$ARTL
$BLPH
$CING
$EIGR
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Medical Specialities
Eloxx Pharmaceuticals Reports Positive Biopsy Results, ELX-02 Shows Promise in Alport Syndrome Treatment
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported results from an assessment of patient biopsies by NIPOKA GmbH (Nipoka). They have developed a highly accurate method for the quantification of podocyte foot process morphology. These results confirm previously reported positive biopsy results from the proof-of-concept Phase 2 open-label clinical trial (NCT05448755) of ELX-02 for the treatment of Nonsense Mutation Alport syndrome patients. Analysis of formalin-fixed paraffin-embedded (FFPE) biopsy samples by Nipoka show ELX-02 treatment improved podocyte foot process morphology with lower effacement in all three pa
10/9/23 8:02:50 AM ET
$ELOX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Eloxx Pharmaceuticals Announces $2M Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380,590 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $5.255 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Eloxx has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 380,590 of its shares of common stock. The warrants will have an exercise price $5.13 per share, will b
9/19/23 8:09:42 AM ET
$ELOX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Eloxx Pharmaceuticals Provides Program Updates On ELX-02 And ZKN-013

Chat with this insight

Recent Analyst Ratings for $ELOX

$ELOX Press Releases

Fastest customizable press release news feed in the world

Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

$ELOX Financials

Live finance-specific insights

Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

Eloxx Pharmaceuticals Acquires Zikani Therapeutics

$ELOX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Eloxx Pharmaceuticals Inc.

SEC Form SC 13G/A filed by Eloxx Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Eloxx Pharmaceuticals Inc. (Amendment)

$ELOX SEC Filings

Eloxx Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

SEC Form NT 10-Q filed by Eloxx Pharmaceuticals Inc.

Eloxx Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

$ELOX Leadership Updates

Live Leadership Updates

Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer

Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer

Eloxx Pharmaceuticals Announces Changes to Board of Directors

$ELOX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Walts Alan Edmund was granted 12,000 shares, increasing direct ownership by 1,274% to 12,942 units (SEC Form 4)

Director Androski Lindsay was granted 12,000 shares (SEC Form 4)

Director Rubin Steven D was granted 12,000 shares (SEC Form 4)

$ELOX Market Insights

Live Market Insights

$ELOX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

12 Health Care Stocks Moving In Friday's After-Market Session

Eloxx Pharmaceuticals Reports Positive Biopsy Results, ELX-02 Shows Promise in Alport Syndrome Treatment

Eloxx Pharmaceuticals Announces $2M Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oppenheimer initiated coverage on Eloxx Pharmaceuticals with a new price target

HC Wainwright & Co. reiterated coverage on Eloxx Pharmaceuticals with a new price target

HC Wainwright & Co. reiterated coverage on Eloxx Pharmaceuticals with a new price target

Recent Analyst Ratings for
$ELOX

$ELOX
Press Releases

$ELOX
Financials

$ELOX
Large Ownership Changes

$ELOX
SEC Filings

$ELOX
Leadership Updates

$ELOX
Insider Trading

$ELOX
Market Insights

$ELOX
Analyst Ratings